Clinical Ink, a global clinical trial data and technology company has acquired Digital Artefacts, a digital endpoint-based technology company with a modular platform for complex cognitive, behavioral, and physiological data capture.
 
“The addition of Digital Artefacts now allows us to drive situational awareness because context matters. Data derived from Digital Artefacts can now increase the richness of our partners’ study data through the convergence of passive and active digital assessments. Their wearables and sensors acumen provides instrumented data collection that complements our existing products and solutions,” said Clinical Ink CEO Ed Seguine. “It continues our commitment to capture data at the source and deliver quantitative insights, empowering our customers to make real-time highly informed decisions.”
 
The combined company will offer:

Scientifically validated neurocognitive assessment and research tools

Combination of standardized eCOA scales/assessments with digital endpoints to produce quantitative patient outcomes

Trial specific remote active and passive behavioral assessment, including wearable and sensor data

Precision Real-World Data and insights across complex therapeutic areas for which cognition is an endpoint

Clinically relevant digital endpoint data collection methodologies including voice, movement, behavior, mood, and other real-world measurements

Scaled delivery capabilities in logistics, helpdesk, project management, and device acquisition/support for DCTs
 
“Our digital endpoint solutions, combined with strong data science, provide expertise that has been foundational with industry recognized partners and top pharma,” noted Joan Severson, co-founder, president, and general manager of Digital Artefacts. “We are very excited to join Clinical Ink and enhance the seamless data collection, cognitive and behavioral assessments, and quantitative outcomes for even the most complex studies.”
 
With this acquisition, Clinical Ink further expands capabilities for decentralized clinical trials with a complete, configurable digital data platform to build studies for specific trial needs.